tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Value
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News WireArrivedEquityMultiple
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Smart Value
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

VERV Stock Latest News

Verve Therapeutics: Buy Rating Driven by FDA Clearance and Strong Market Potential
RatingsVerve Therapeutics: Buy Rating Driven by FDA Clearance and Strong Market Potential
6d ago
VERV
Positive Outlook for Verve Therapeutics: Buy Rating Backed by FDA Clearance and Promising Developments
PremiumRatings
Positive Outlook for Verve Therapeutics: Buy Rating Backed by FDA Clearance and Promising Developments
6d ago
VERV
Positive Outlook for Verve Therapeutics: Buy Rating Driven by Promising VERVE-102 Trial Data and Design Improvements
PremiumRatings
Positive Outlook for Verve Therapeutics: Buy Rating Driven by Promising VERVE-102 Trial Data and Design Improvements
6d ago
VERV
Promising Outlook for Verve Therapeutics: FDA Clearance and Strategic Partnership Drive Buy Rating
PremiumRatings
Promising Outlook for Verve Therapeutics: FDA Clearance and Strategic Partnership Drive Buy Rating
6d ago
VERV
Verve Therapeutics announces FDA clearance of IND application for VERVE-102
PremiumThe Fly
Verve Therapeutics announces FDA clearance of IND application for VERVE-102
7d ago
VERV
Verve Therapeutics price target lowered to $15 from $17 at RBC Capital
PremiumThe FlyVerve Therapeutics price target lowered to $15 from $17 at RBC Capital
27d ago
VERV
Promising Progress and Strategic Partnerships Position Verve Therapeutics as a Compelling Buy Opportunity
Premium
Ratings
Promising Progress and Strategic Partnerships Position Verve Therapeutics as a Compelling Buy Opportunity
1M ago
VERV
Verve Therapeutics: Buy Rating Backed by Promising VERVE-102 Program and Strategic Catalysts
Premium
Ratings
Verve Therapeutics: Buy Rating Backed by Promising VERVE-102 Program and Strategic Catalysts
1M ago
VERV
Buy Rating for Verve Therapeutics: Promising Program Progress and Strong Financial Position
PremiumRatings
Buy Rating for Verve Therapeutics: Promising Program Progress and Strong Financial Position
1M ago
VERV
Verve Therapeutics price target raised to $15 from $14 at H.C. Wainwright
PremiumThe Fly
Verve Therapeutics price target raised to $15 from $14 at H.C. Wainwright
1M ago
VERV
Verve Therapeutics Reports 2024 Financial Results and Pipeline Progress
PremiumCompany Announcements
Verve Therapeutics Reports 2024 Financial Results and Pipeline Progress
1M ago
VERV
Verve Therapeutics reports Q4 EPS (58c), consensus (67c)
PremiumThe Fly
Verve Therapeutics reports Q4 EPS (58c), consensus (67c)
1M ago
VERV
Is VERV a Buy, Before Earnings?
PremiumPre-EarningsIs VERV a Buy, Before Earnings?
1M ago
VERV
Promising Outlook for Verve Therapeutics: Buy Rating Backed by Innovative Treatments and Strategic Partnerships
Premium
Ratings
Promising Outlook for Verve Therapeutics: Buy Rating Backed by Innovative Treatments and Strategic Partnerships
1M ago
VERV
Optimistic Outlook for Verve Therapeutics Amid Promising Developments and Strategic Partnerships
Premium
Ratings
Optimistic Outlook for Verve Therapeutics Amid Promising Developments and Strategic Partnerships
1M ago
VERV
Buy Rating for Verve Therapeutics: VERVE-102’s Enhanced Safety and Promising Efficacy Boost Investor Confidence
PremiumRatings
Buy Rating for Verve Therapeutics: VERVE-102’s Enhanced Safety and Promising Efficacy Boost Investor Confidence
2M ago
VERV
Verve Therapeutics announces anticipated 2025 milestones
PremiumThe Fly
Verve Therapeutics announces anticipated 2025 milestones
3M ago
LLY
VERV
Verve Therapeutics sees cash runway into mid-2027
PremiumThe Fly
Verve Therapeutics sees cash runway into mid-2027
3M ago
VERV
Verve Therapeutics has positive read from NewAmsterdam data, says Stifel
PremiumThe Fly
Verve Therapeutics has positive read from NewAmsterdam data, says Stifel
4M ago
NAMS
VERV
Verve Therapeutics price target lowered to $17 from $20 at RBC Capital
PremiumThe FlyVerve Therapeutics price target lowered to $17 from $20 at RBC Capital
5M ago
VERV
Verve Therapeutics price target raised to $32 from $29 at Canaccord
Premium
The Fly
Verve Therapeutics price target raised to $32 from $29 at Canaccord
5M ago
VERV
Verve Therapeutics price target lowered to $14 from $15 at H.C. Wainwright
Premium
The Fly
Verve Therapeutics price target lowered to $14 from $15 at H.C. Wainwright
5M ago
VERV

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >